Today the U.S. Court of Appeals for the Federal Circuit issued its much-anticipated opinion in Association for Molecular Pathology (AMP) and ACLU v. USPTO and Myriad Genetics (Fed. Cir. 2012). In the decision, the Court held that claims directed to isolated DNA molecules and methods of screening potential anti-cancer therapeutics are patent-eligible subject matter.
About IP SpotlightIP Spotlight provides news and practice tips relating to the legal and business aspects of intellectual property and other intangible assets. Topics include licensing, due diligence, acquisition, compliance and risk management associated with patents, trademarks, copyrights and trade secrets. IP Spotlight is published by Jim Singer of Fox Rothschild LLP.
About the Author
Jim Singer is a partner with the law firm of Fox Rothschild LLP, where he focuses on intellectual property acquisition, protection, enforcement and licensing. For more details and contact information, select the "About the Author" link below.
Subscribe via RSS
Subscribe via Email
DisclaimerThe individuals who maintain this blog work at Fox Rothschild LLP. The information, comments and links posted on this blog do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the blog and/or the blogger. For legal advice, contact an attorney at Fox Rothschild LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the blogger; neither Fox Rothschild nor the blogger will assume any liability or responsibility for it. If you send any information, documents or materials to the blog, you give permission for the blogger to include them on or in the blog. No information, documents or materials you send to the blog will be considered confidential or privileged by Fox Rothschild or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the blogger.